This is an open-label Study administering GBT021601 as a single oral dose of 200 mg in healthy participants.
An Open-label Study of GBT021601 in 8 to 10 healthy male or female participants to evaluate the absorption, distribution, metabolism, and excretion (ADME) of GBT021601.